💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Erlotinib Hydrochloride

CHEMBL1079742 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
429.9 g/mol
LogP
—
Phase
4

The hydrochloride salt form of erlotinib, this targeted cancer drug blocks the EGFR signaling pathway to slow the growth of EGFR-mutated tumors. The hydrochloride salt formulation is used in standard oral capsules.

น้ำหนักโมเลกุล

429.9000 g/mol

TPSA

74.70 Ų

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Chronic Pain Hepatitis C Prostate Cancer Colorectal Cancer Leukemia

กลไกการออกฤทธิ์

Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H24ClN3O4

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
พันธะที่หมุนได้

                        
11

                    

                    
                    
                    

                        
อะตอมหนัก

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
The hydrochloride salt form of erlotinib, this targeted cancer drug blocks the EGFR signaling pathway to slow the growth of EGFR-mutated tumors. The hydrochloride salt formulation is used in standard oral capsules.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Erlotinib Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1079742.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 176871.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.